Compare FWDI & RGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FWDI | RGNX |
|---|---|---|
| Founded | 1961 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Plastic Products | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 560.0M | 487.2M |
| IPO Year | 2014 | 2015 |
| Metric | FWDI | RGNX |
|---|---|---|
| Price | $4.92 | $7.65 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 11 |
| Target Price | $11.83 | ★ $21.40 |
| AVG Volume (30 Days) | ★ 1.3M | 1.2M |
| Earning Date | 12-10-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 18.08 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $18,187,525.00 | $10,393,000.00 |
| Revenue This Year | $216.73 | N/A |
| Revenue Next Year | N/A | $59.15 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 126.48 |
| 52 Week Low | $3.48 | $5.46 |
| 52 Week High | $9.28 | $16.19 |
| Indicator | FWDI | RGNX |
|---|---|---|
| Relative Strength Index (RSI) | 31.78 | 50.75 |
| Support Level | $3.91 | $6.79 |
| Resistance Level | $5.05 | $8.31 |
| Average True Range (ATR) | 0.45 | 0.60 |
| MACD | -0.16 | 0.12 |
| Stochastic Oscillator | 5.42 | 50.65 |
Forward Industries Inc is a Solana-focused digital asset treasury company, with the idea to buy, hold, stake, trade, invest in, and grow SOL and SOL-related digital assets, protocols, and businesses. Its mission is to expand and strengthen the Solana ecosystem by acquiring and staking SOL and engaging with, providing tools to, and investing in the Solana network, Solana developers, and Solana-related projects in order to increase shareholder value. In connection with a private placement transaction in September 2025, it launched a digital asset treasury idea supported by investors and operating partners, including Galaxy Digital and Jump Crypto.
Regenxbio Inc is a clinical-stage biotechnology company focused on the development of gene therapy treatments. Its product candidates are designed to deliver genes to cells to address genetic defects or enable the production of therapeutic proteins. The company is developing a pipeline of investigational gene therapy treatments using its NAV Technology Platform based on adeno-associated virus (AAV) vectors. Its internal research and development programs are focused on therapies for retinal, neuromuscular, and neurodegenerative diseases.